Trevena
Clinical stage biopharmaceutical company discovering and developing g-protein coupled receptors (gpcr) biased ligands.
Market cap
$959k
Enterprise value
$25m
Share price
$1.05 TRVN
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $2.0m | Post IPO Debt | |
| Total Funding | 000k | ||
Forest Laboratories(exited)
HealthCare Ventures(exited)
Polaris Partners(exited)
NEA(exited)
Alta Partners(exited)
CBC Group(exited)
Jonathan Violin(exited)
| USD | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (1471 %) | (99 %) | 9800 % | (82 %) | (174 %) | (848 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 16410 % | (474 %) | (74961 %) | (961 %) | (9158 %) | 13487 % | (1218 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 17193 % | (537 %) | (80229 %) | (957 %) | (9098 %) | 12839 % | (1289 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | (11716 %) | 276 % | 42874 % | 428 % | 2368 % | (4357 %) | 523 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads